by Stephanie Wood Miller | May 20, 2024 | Weekly News
Today is all about reclassifying marijuana from a Schedule I to a Schedule III drug and the impact it may have or may not have in the U.S. We’ve included a perspective from the Washington D.C.’s The Hill, Kyle Jaeger at Marijuana Moment, the ACLU and our own scientist...
by Vita Maziveyi | May 13, 2024 | Weekly News
On June 4th, 2024, the National Center for Complementary and Integrative Health (NCCIH), a branch of the National Institutes of Health (NIH), will convene a landmark open meeting aimed at unlocking the mysteries of cannabis. With a keen focus on the plant’s...
by Vita Maziveyi | May 6, 2024 | Science, Weekly News
Why we Think This is Important Understanding patterns of tobacco and cannabis use during pregnancy is crucial for safeguarding maternal and fetal health. The PATH study provides valuable insights into the prevalence of co-use before, during, and after pregnancy,...
by Stephanie Wood Miller | Apr 30, 2024 | Science, Weekly Cannabis News, Weekly News
According to Associated Press this morning the FDA will move to reclassify marijuana from a Schedule I to a Schedule III drug. Schedule I drugs have a high potential for abuse and no accepted medical use, while Schedule III drugs have a lower potential for abuse and...
by Vita Maziveyi | Apr 29, 2024 | Science, Weekly News
Why We Think It’s Important: This article is important as it provides valuable insights into the acute neurocognitive effects of CannEpil, a medicinal cannabis oil, shedding light on its potential therapeutic benefits and safety profile in treating various medical...
by Stephanie Wood Miller | Apr 22, 2024 | Weekly Cannabis News, Weekly News
All the news this week points to changing attitudes toward cannabis at both the federal and state level. Cannabis seems to be one thing Americans can agree on and the hemp industry settles down after a wild ride the past few years. Three out of five Americans think...